Impact BioMedical Inc. (IBO)
| Market Cap | 26.98M +263.0% |
| Revenue (ttm) | 35,000 +400.0% |
| Net Income | 791,000 |
| EPS | 0.07 |
| Shares Out | 8.54M |
| PE Ratio | 51.37 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,041 |
| Open | 2.990 |
| Previous Close | 3.403 |
| Day's Range | 2.990 - 3.520 |
| 52-Week Range | 2.620 - 10.475 |
| Beta | 2.73 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About IBO
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can i... [Read more]
Financial Performance
Financial StatementsNews
Impact Biomedical Inc trading resumes
10:09 EDT Impact Biomedical (IBO) Inc trading resumes
Impact Biomedical Inc trading halted, volatility trading pause
10:04 EDT Impact Biomedical (IBO) Inc trading halted, volatility trading pause
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited)
HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (NYSE: IBO) (the “Company” or “Impact”) announced that a Form F-4 registration statement (the “Registration Statement”) was filed wit...
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc....
Impact BioMedical announces 1 for 12.62 reverse stock split
Impact BioMedical (IBO) announced that the company’s Board of Directors has approved a 1 for 12.62 reverse stock split of the company’s issued and outstanding common stock. The reverse stock…
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley's Ltd.
HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (the “Company”) today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's...
Impact BioMedical Quarterly report: Q2 2026
Impact BioMedical has published its Q2 2026 quarterly earnings report on August 7, 2026.
Impact BioMedical Quarterly report: Q1 2026
Impact BioMedical has published its Q1 2026 quarterly earnings report on May 12, 2026.
Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
HOUSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, in...
Impact BioMedical Annual report: Q4 2025
Impact BioMedical has published its Q4 2025 annual report on March 11, 2026.
Why Is Impact BioMedical Stock (IBO) Up Today?
Impact BioMedical stock rallied after the company announced an amended merger agreement.
Impact BioMedical Quarterly report: Q3 2025
Impact BioMedical has published its Q3 2025 quarterly earnings report on November 7, 2025.
Impact BioMedical Proxy statement: Proxy Filing
Impact BioMedical filed a proxy statement on September 22, 2025, providing details for shareholder voting and corporate governance matters.
Impact BioMedical announces 3F U.S. patent issue
Impact Biomedical (IBO) announces that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition and Method of Controlling Infectious Diseases with Functional F...
Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue
HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition an...
Impact BioMedical Quarterly report: Q2 2025
Impact BioMedical has published its Q2 2025 quarterly earnings report on August 14, 2025.
Why Is Impact BioMedical Stock (IBO) Up 200% Today?
Impact BioMedical stock soared on Monday after the company announced a merger agreement with Dr Ashleys Limited.
Impact BioMedical, Dr Ashleys enter strategic merger agreement
Dr Ashleys Limited and Impact BioMedical (IBO) announced the execution of a merger and share exchange agreement on June 21, 2025 to enter into a strategic merger transaction. Upon closing…
Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company (“Dr Ashleys”), and Impact BioMedical Inc. (“Impact BioMedical”) (NYSE American: IBO), a...
Impact BioMedical Quarterly report: Q1 2025
Impact BioMedical has published its Q1 2025 quarterly earnings report on May 14, 2025.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Impact BioMedical (IBO), 1,430% surge in interest MAIA Bi...
Impact BioMedical Annual report: Q4 2024
Impact BioMedical has published its Q4 2024 annual report on March 28, 2025.
Impact Biomedical Inc. Announcement Stock Activity/Pricing
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare so...
Impact BioMedical announces acquisition of Celios in $1.15M equity transaction
Impact BioMedical (IBO) announced the acquisition of Celios in a strategic, all equity transaction valued at approximately $1.15M. This acquisition aligns with Impact Biomedical’s focused roll-up stra...
DSS announces sale of Celios to Impact BioMedical
DSS (DSS) announced the sale of its Celios air purification asset to Impact BioMedical (IBO) in a strategic, all-equity transaction valued at approximately $1.15M. This divestiture aligns with DSS’ on...